74168-69-7

Basic information

• Product Name: 5-Chlorothiophene-2-ylmethanol
• Synonyms: 5-Chlorothiophene-2-ylmethanol;5-CHLOROTHIOPHEN-2-YLMETHANOL;5-Chloro-2-thiophenemethanol;5-Chlorothiophene-2-metha...;5-Chlorothiophene-2-Methanol;(5-Chlorothiophen-2-yl)
• CAS NO: 74168-69-7
• Molecular Formula: C₅H₅ClOS
• Molecular Weight: 148.61
• Product Categories: CHIRAL CHEMICALS
• Mol File: 74168-69-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 160℃/20Torr
• Flash Point: 92.8 °C
• Appearance: /
• Density: 1.419 g/cm³
• Vapor Pressure: 0.0381mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-Chlorothiophene-2-ylmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chlorothiophene-2-ylmethanol(74168-69-7)
• EPA Substance Registry System: 5-Chlorothiophene-2-ylmethanol(74168-69-7)

Safety Data

• Hazardous Substances Data: 74168-69-7(Hazardous Substances Data)

Usage

General Description

5-Chlorothiophene-2-ylmethanol is a chemical compound that belongs to the class of thiophenes. It is a colorless to pale yellow liquid with a molecular formula of C6H5ClOS. 5-Chlorothiophene-2-ylmethanol is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a building block for the production of other organic compounds. 5-Chlorothiophene-2-ylmethanol is known for its strong and distinct odor and should be handled with care due to its potential health hazards and toxicity.

InChI:InChI=1/C5H5ClOS/c6-5-2-1-4(3-7)8-5/h1-2,7H,3H2

Upstream product

• 7283-96-7 5-Chloro-2-thiophenecarboxaldehyde 
• 5751-82-6 ethyl 5‐chlorothiophene‐2‐carboxylate 
• 23784-96-5 2-Chloro-5-(chloromethyl)thiophene 

Downstream Products

• 23784-96-5 2-Chloro-5-(chloromethyl)thiophene 

Relevant articles and documents

Azacyclo diketone compound and preparation method thereof

The invention provides an azacyclo diketone compound, which is a compound represented by the following structure defined in the specification, or a pharmaceutically acceptable salt thereof. The invention provides a compound having an inhibitory activity on influenza (flu) virus proliferation, particularly on influenza-related cap-dependent endonuclease to inhibit influenza virus proliferation so as to treat or prevent influenza. The present invention relates to a substituted azacyclo diketone compound having inhibitory activity on cap-dependent endonuclease, and a pharmaceutical composition containing the substituted azacyclo diketone compound.

Novel M2-selective, Gi-biased agonists of muscarinic acetylcholine receptors

Background and Purpose: More than 30% of currently marketed medications act via GPCRs. Thus, GPCRs represent one of the most important pharmacotherapeutic targets. In contrast to traditional agonists activating multiple signalling pathways, agonists activating a single signalling pathway represent a new generation of drugs with increased specificity and fewer adverse effects. Experimental Approach: We have synthesized novel agonists of muscarinic ACh receptors and tested their binding and function (on levels of cAMP and inositol phosphates) in CHO cells expressing individual subtypes of muscarinic receptors, primary cultures of rat aortic smooth muscle cells and suspensions of digested native tissues from rats. Binding of the novel compounds to M2 receptors was modelled in silico. Key Results: Two of the tested new compounds (1-(thiophen-2-ylmethyl)-3,6-dihydro-2H-pyridinium and 1-methyl-1-(thiophen-2-ylmethyl)-3,6-dihydro-2H-pyridinium) only inhibited cAMP synthesis in CHO cells, primary cultures, and native tissues, with selectivity for M2 muscarinic receptors and displaying bias towards the Gi signalling pathway at all subtypes of muscarinic receptors. Molecular modelling revealed interactions with the orthosteric binding site in a way specific for a given agonist followed by agonist-specific changes in the conformation of the receptor. Conclusions and Implications: The identified compounds may serve as lead structures in the search for novel non-steroidal and non-opioid analgesics acting via M2 and M4 muscarinic receptors with reduced side effects associated with activation of the phospholipase C signalling pathway.

Benzoxazine compound and its preparation methods and application

The invention relates to a benzoxazine compound represented in the following formula 1. The benzoxazine compound can serve as a beta 2 receptor agonist. The formula can be seen from the description.